EACS 2017 Podcast

EACS 17 Podcast Theme

EACS Podcast Button 

About the Program:

Program Overview:

The ARV Therapies and Therapeutic Strategies program is a comprehensive, independent review of the 16th European AIDS Conference (EACS 2017). This program consists of five components: (1) EACS 2017 Expert Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) European Perspective on EACS 2017**: a 1.5 hour Case-based Internet symposium featuring Europe based expert faculty reviewing and discussing key presentations with a focus on clinical management and treatment in the EU; (3) Comprehensive Expert Review and Discussion of Key Presentations: an on-line, in-depth review of 8 of the key poster/presentations reviewed in the Internet symposium (4) Rapid-Fire Review of EACS 2017: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (5) From Conference to Clinic: Reviewing and Applying Data From EACS 2017: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care.

The Rapid-Fire Review of EACS 2017 features our national faculty panel briefly reviewing the most essential information and data from EACS 2017. This activity will enable participating health care providers caring for HIV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care. 

All online components of the program can be accessed at www.viraled.com

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at EACS 2017 and it is not sanctioned by the organizers of EACS 2017.

 ** The European Perspective on EACS 2017 component is jointly provided by the Annenberg Center for Health Sciences at Eisenhower and ViralEd, Inc. in collaboration with Postgraduate Institute for Medicine and supported by an independent educational grant from ViiV Healthcare.  

Back to Top

Target Audience:

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.

Back to Top

Learning Objectives:

After completing this activity, the participant should be better able to:

  • Use data reported at EACS 2017 for counseling, testing and antiretroviral treatment to prevent HIV infection, especially in underserved communities
  • Use in a clinical setting findings from key studies on HIV/AIDS diagnosis, management, and treatment presented at EACS 2017
  • Employ strategies based on studies and data presented at EACS 2017 for helping HIV-positive patients in medically underserved communities link to and stay in appropriate and effective HIV care
  • Discuss with patients and colleagues the studies and data on therapies for HIV/AIDS presented at EACS 2017 and use that discussion to decide on appropriate planning of therapy for patients with HIV/AIDS

Release Date: November 3, 2017

Expiration Date: November 3, 2018

Estimated time to complete the Podcast: 45 minutes

Media: Internet

 

Back to Top

 

Faculty:


José Arribas, MD
Senior Attending Physician, HIV Unit
Hospital de La Paz
Madrid, Spain 

Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine I
University Hospital
Bonn, Germany

Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine
at the University of Pennsylvania
Philadelphia, Pennsylvania

Renslow Sherer, MD
Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois
Graeme Moyle, MD, MB, BS
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom
 
Back to Top


Physician Continuing Medical Education:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest:

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Jose Arribas, MD:

  • Consulting Fees: Merck, Gilead
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest: ViiV, Janssen, Abbvie, BMS, Gilead, Merck

Ian Frank, MD:

  • Consulting Fees: Gilead
  • Contracted Research: ViiV/GlaxoSmithKline

Graeme Moyle, MD:

  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest: BMS, Gilead, Merck, Tobira/Allergen, Teva, Mylan

Juergen Rockstroh, MD:

  • Consulting Fees: Abbott, AbbVie, Gilead, Hexal, Janssen, Merck, ViiV
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest: Abbott, Gilead, Merck
  • Contracted Research: Gilead
Renslow Sherer, MD:
  • Consulting Fees: Gilead

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Back to Top

Disclosure of Unlabeled Use:

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planner. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Back to Top

Instructions for Participation and Credit:

There are no fees for participating and receiving CME credit for this activity. During the period, November 3, 2017 through November 3, 2018, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on www.cmeuniveristy.com. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 12248. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

Back to Top

Disclaimer:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Back to Top

PIM_small

VE logo 300px 

Supported by an independent educational grant from Gilead Sciences Medical Affairs.

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at EACS 2017 and it is not sanctioned by EACS 2017.


Prepare to print

Share this page:

Get link code to this page                     


Back to Top